Clicky

Selvita S.A.(SLV)

Description: Selvita S.A. operates as a contract research organization in Poland, rest of Europe, the United States, and internationally. It operates in two segments, Contract Research Organization (CRO) services, and Bioinformatics. The company offers drug discovery services in the areas of assay development and screening, medicinal and synthetic chemistry, computer-aided drug design/ artificial intelligence, structural biology, in vitro/ In Vivo pharmacology, ADME/DMPK and analytical testing. It also provides pharma services in the field of drug testing and bioanalytical analysis, including development and optimization, validation and transfer, stability studies, quality control, and regulatory aspects support services. In addition, the company offers research and development services in the areas of process research, laboratory scale custom synthesis of NCEs, industrial chemistry, and synthesis of isotopically labelled compounds, as well as other services for the agrochemical industry. Further, it provides bio-data science and advanced software services to data-driven life science and healthcare organizations. Selvita S.A. was founded in 2007 and is headquartered in Krakow, Poland.


Keywords: Life Sciences Health Sciences Pharmacology Drug Discovery Software Services Biochemistry Bioinformatics Healthcare Organizations Contract Research Organizations Drug Design Wuxi Apptec Drug Discovery Services Contract Research Organization Pharma Services

Home Page: selvita.com

ul. Bobrzynskiego 14
Kraków, 30-348
Poland
Phone: 48 122 97 47 00


Officers

Name Title
Mr. Boguslaw Stanislaw Sieczkowski M.B.A. Chairman of Management Board & CEO
Dr. Milosz Kazimierz Gruca Ph.D. Chief Commercial Officer, Exec. VP & VP of Management Board
Mr. Dariusz Tomasz Kurdas Chief Financial Officer & Member of the Management Board
Dr. Miroslawa Monika Zydron Ph.D. COO & Member of the Management Board
Mr. Dawid Patryk Radziszewski Gen. Counsel & Member of the Management Board
Dr. Adrijana Vinter Global Head of Drug Discovery & Member of the Management Board

Exchange: WAR

Country: PL

Currency: Polish złoty (zł)

Forward PE: 0
Trailing PE: 62.5899
Price-to-Book MRQ: 6.0986
Price-to-Sales TTM: 3.7349
IPO Date:
Fiscal Year End: December
Full Time Employees: 878
Back to stocks